How Far Is Too Far? The Ethics of Mini Brain Research
December 11, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Sprycel
(United States) [Available]Synonyms :
dasatinib
Class :
Antineoplastics and Tyrosine Kinase Inhibitor
Brand Name :
Sprycel
(United States) [Available]Synonyms :
dasatinib
Class :
Antineoplastics and Tyrosine Kinase Inhibitor
dasatinib may enhance the QTc-prolonging effect of QT-prolonging
dasatinib may enhance the QTc-prolonging effect of QT-prolonging
dasatinib may enhance the QTc-prolonging effect of QT-prolonging
dasatinib may enhance the QTc-prolonging effect of QT-prolonging
dasatinib may enhance the QTc-prolonging effect of QT-prolonging
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may have an increased QTc-prolonging effect when combined with dasatinib
may have an increased QTc-prolonging effect when combined with dasatinib
may have an increased QTc-prolonging effect when combined with dasatinib
may have an increased QTc-prolonging effect when combined with dasatinib
may have an increased QTc-prolonging effect when combined with dasatinib
antacids: they may diminish the serum concentration of dasatinib
antacids: they may diminish the serum concentration of dasatinib
antacids: they may diminish the serum concentration of dasatinib
antacids: they may diminish the serum concentration of dasatinib
antacids: they may diminish the serum concentration of dasatinib
dasatinib: they may diminish the serum concentration of antacids
dasatinib: they may diminish the serum concentration of antacids
dasatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
dasatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
dasatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
dasatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
dasatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
dasatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
dasatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
dasatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
may enhance the serum concentration of CYP3A4 inhibitors
may increase the hepatotoxic effect of acetaminophen
may diminish the serum concentration of CYP3A4 Inducers
may have an increased hepatotoxic effect when combined with dasatinib
may increase the hepatotoxic effect of acetaminophen
acetaminophen/doxylamine/dextromethorphan
may increase the CNS depressant effect CNS Depressants
dasatinib and loperamide are both known to elevate the QTc interval
it may enhance the qtc interval when combined with lofexidine
dasatinib together with cisapride lead to an elevation of the QTc interval
QTc interval is increased both by lenvatinib and dasatinib
may increase the QT-prolonging effect and enhance the risk of ventricular arrhythmias
CYP3A strong enhancers of the small intestine may reduce the bioavailability of dasatinib
when both drugs are combined, there may be an increase in the QTC interval
may increase the QTc interval when combined
It may enhance QTc interval when combined with pentamidine
Aminosalicylic Acid Derivatives
It may enhance the effect of Myelosuppressive Agents
May have an increased anticoagulant effect when combined with Antiplatelet agents
May have an increased anticoagulant effect when combined with Antiplatelet agents
May have an increased anticoagulant effect when combined with Antiplatelet agents
May have an increased anticoagulant effect when combined with Antiplatelet agents
May have an increased anticoagulant effect when combined with Antiplatelet agents
it increases the effect of anticoagulants
it increases the effect of anticoagulants
it increases the effect of anticoagulants
it increases the effect of anticoagulants
it increases the effect of anticoagulants
It may enhance QTc interval when combined with perphenazine
It may enhance the effect when combined with miconazole vaginal by affecting CYP3A4 metabolism
dasatinib can impact the hepatic/intestinal enzyme CYP3A4 metabolism, leading to an elevation in the level or potency of intranasal midazolam
dasatinib: they may increase the anticoagulant effect antiplatelet properties
dasatinib: they may increase the anticoagulant effect antiplatelet properties
when bromazepam and dasatinib are used together, there is a potential reduction in the bromazepam's metabolism
Combining tegafur with dasatinib can reduce tegafur’s metabolism
When alprazolam and dasatinib is used together, this leads to reduction in the alprazolam’s metabolism
When dasatinib is used together with somatotropin, this leads to a rise in dasatinib metabolism
dasatinib: they may increase the CNS depressant effect of CNS Depressants
dasatinib: they may increase the CNS depressant effect of CNS Depressants
dasatinib: they may increase the CNS depressant effect of CNS Depressants
dasatinib: they may increase the CNS depressant effect of CNS Depressants
dasatinib: they may increase the CNS depressant effect of CNS Depressants
When ponesimod is used together with dasatinib, this leads to enhanced risk or seriousness of bradycardia
When dasatinib is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When dasatinib is used together with givinostat, this leads to enhanced risk or seriousness of Qtc prolongation
dasatinib: they may enhance the serum concentration of CYP2D6 Inhibitors
dasatinib: they may enhance the serum concentration of CYP2D6 Inhibitors
dasatinib: they may enhance the serum concentration of CYP2D6 Inhibitors
dasatinib: they may enhance the serum concentration of CYP2D6 Inhibitors
dasatinib: they may enhance the serum concentration of CYP2D6 Inhibitors
When dasatinib is used together with oleandomycin, this leads to enhanced concentration serum of dasatinib
When dasatinib is used together with ridaforolimus, this leads to enhanced concentration serum of dasatinib
dasatinib: it may enhance the toxic effect of Anti-Inflammatory Agents
dasatinib: it may enhance the toxic effect of Anti-Inflammatory Agents
aspirin, chlorpheniramine, and phenylephrine
dasatinib: it may enhance the toxic effect of Anti-Inflammatory Agents
dasatinib: it may enhance the toxic effect of Anti-Inflammatory Agents
dasatinib: it may enhance the toxic effect of Anti-Inflammatory Agents
dasatinib: it may increase the metabolism of cerivastatin
when both drugs are combined, there may be a decreased metabolism of etoposide
when both drugs are combined, there may be an increased metabolism of dasatinib
when both drugs are combined, there may be an increased risk or severity of adverse effects
the effect of dasatinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, both increase the QTC interval
fedratinib increases the effect of dasatinib by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
osimertinib and dasatinib, when used simultaneously, increase the QTc interval
may increase the anti-coagulant action of anti-coagulants
may increase the anti-coagulant effect of antiplatelet agents
may increase the risk or severity of toxic effects when combined
the efficacy of the vaccine may be reduced
the activity of the anthrax vaccine can be reduced when used in combination with dasatinib
it increases the effect or level of finasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
it increases the effect or level of dutasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
The growth, proliferation, and survival of malignant hematopoietic cells are caused by the dysregulation of BCR-ABL’s tyrosine kinase activity in individuals with chronic myeloid leukemia (CML).
Dasatinib has a greater affinity than imatinib for both the active and inactive conformations of the ABL kinase domain.
Dasatinib suppresses cell proliferation in cell lines overexpressing BCR-ABL in acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML).
Adverse drug reactions:
Frequency defined
>10%
Asthenia
Mouth ulceration
Musculoskeletal pain
Upper respiratory tract infection
Diarrhea
Rash
Paronychia
Stomatitis
Anemia
Cough
Conjunctivitis
Nausea
Hyperbilirubinemia
Dyspnea
Dermatitis
Insomnia
1-10%
Skin fissures
Dysgeusia
Skin exfoliation/exfoliative skin reactions
Interstitial lung disease
Keratitis
Chest pain
Fatigue
Vomiting
None
Contraindication:
None
Caution:
Myelosuppression
Bleeding
Pulmonary arterial hypertension
Patients with chronic phase CML and pediatric Ph+ ALL
Hepatotoxicity
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
In clinical studies, 1% of patients treated with dasatinib exhibited a QTcF greater than 500 ms, while less than 1% of patients experienced QTc prolongation as an adverse event.
In children, it may also result in negative reactions related to bone growth and development and embryo-fetal toxicity.
It is taken orally in tablet form with or without food.
Take in the morning or the evening at the same time every day. It should be swallow as whole at time.
Don’t chew or crush the pellets. Avoid drinking grapefruit juice.
Avoid taking two doses at once; skip the first one and take the following one at the scheduled time.
Patient information leaflet
Generic Name: dasatinib
Why do we use dasatinib?
Adults with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase that is Philadelphia chromosome-positive (Ph+) may be treated with dasatinib.
Children aged one year and up with Ph+ CML in the chronic phase or newly diagnosed Ph+ ALL who are receiving chemotherapy can also be treated with dasatinib.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
